April 29, 2024 – Biologics by McKesson, an unbiased specialty pharmacy specializing in oncology and uncommon illnesses, was chosen by Day One Biopharmaceuticals as a specialty pharmacy with a restricted community for OJEMDAT.M (tovorafenib) for the therapy of low-grade glioma in kids (pLGG).
OJEMDA, which has been designated Uncommon Pediatric Illness and authorized by the U.S. Meals and Drug Administration (FDA) on April 23, 2024, is an oral, brain-penetrating, extremely selective sort II RAF kinase inhibitor for the therapy of pLGG. Though pLGGs are thought-about a slow-growing tumor, they press on surrounding components of the mind, affecting its operate.
For extra details about the signs, analysis and therapy of pLGG, click on right here. For extra details about OJEMDA, together with full prescribing info, click on right here.
Study extra